Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes

Journal of Clinical Endocrinology and Metabolism

Volumn 91, Issue 11, 2006, Pages 4612-4619

  Herman, Gary A ^a   Bergman, Arthur ^a   Stevens, Catherine ^a   Kotey, Paul ^a   Yi, Bingming ^a   Zhao, Peng ^a   Dietrich, Bruno ^b   Golor, George ^b   Schrodter, Andreas ^c   Keymeulen, Bart ^d   Lasseter, Kenneth C ^e   Kipnes, Mark S ^f   Snyder, Karen ^a   Hilliard, Deborah ^a   Tanen, Michael ^a   Cilissen, Caroline ^g   De Smet, Marina ^g   De Lepeleire, Inge ^g   Van Dyck, Kristien ^g   Wang, Amy Q ^a   Zeng, Wei ^a   Davies, Michael J ^a   Tanaka, Wesley ^a   Holst, Jens J ^h   Deacon, Carolyn F ^h   Gottesdiener, Keith M ^a   Wagner, John A ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

^b ClinicalResearch AG   (Germany)

^c Focus Clinical Drug Development GmbH   (Germany)

^d FREE UNIVERSITY OF BRUSSELS   (Belgium)

^e Clinical Pharmacology Associates Miami   (United States)

^f Diabet/Glandular Dis Res Assoc   (United States)

^g MSD Europe Inc   (Belgium)

^h UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; INSULIN; ORAL ANTIDIABETIC AGENT; PLACEBO; SITAGLIPTIN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

EID: 33749871472     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2006-1009     Document Type: Article

References (22)

1. Mest HJ, Mentlein R 2005 Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. Diabetologia 48:616-620
2. Ahren B, Schmitz O 2004 GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res 36:867-876
3. Holst JJ, Gromada J 2004 Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 287:E199-E206
4. Reimer MK, Holst JJ, Ahren B 2002 Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. Eur J Endocrinol 146:717-727
5. Ahren B, Holst JJ, Martensson H, Balkan B 2000 Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. Eur J Pharmacol 404:239-245
6. Pospisilik JA, Stafford SG, Demuth HU, Brownsey R, Parkhouse W, Finegood DT, McIntosh CH, Pederson RA 2002 Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and β-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes 51:943-950
7. Ahren B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A 2004 Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 89:2078-2084
8. Ahren B, Simonsson E, Larsson H, Landin-Olsson M, Torgeirsson H, Jansson PA, Sandqvist M, Bavenholm P, Efendic S, Eriksson JW, Dickinson S, Holmes D 2002 Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 25:869-875
9. Ahren B, Gomis R, Standl E, Mills D, Schweizer A 2004 Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 27:2874-2880
10. Kim D, Wang L, Beconi M, Eiermann GJ, Fisher MH, He H, Hickey GJ, Kowalchick JE, Leiting B, Lyons K, Marsilio F, McCann ME, Patel RA, Petrov A, Scapin G, Patel SB, Roy RS, Wu JK, Wyvratt MJ, Zhang BB, Zhu L, Thornberry NA, Weber AE 2005 (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3- a]pyrazin-7(8H)-yl]1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 48:141-151
11. Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, Snyder K, Hilliard D, Tanen M, Tanaka W, Wang AQ, Chen L, Zeng W, Musson D, Laethem M, Zhou YY, Winchell G, Davies MJ, Ramael S, Gottesdiener KM, Wagner JA 2005 Pharmacokinetics and pharmacodynamics of single doses of sitagliptin, an inhibitor of dipeptidyl peptidase-IV, in healthy subjects. Clin Pharm Ther 78:675-688
12. Krarup T, Holst JJ 1984 The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera. Regul Pept 9:35-46
13. Krarup T, Madsbad S, Moody AJ, Regeur L, Faber OK, Holst JJ, Sestoft L 1983 Diminished immunoreactive gastric inhibitory polypeptide response to a meal in newly diagnosed type I (insulin-dependent) diabetics. J Clin Endocrinol Metab 56:1306-1312
14. Deacon CF, Nauck MA, Meier J, Hucking K, Holst JJ 2000 Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 85:3575-3581
15. Hartley HO 1961 The modified Gauss-Newton method for the fitting of nonlinear regression functions by least squares. Technometrics 3:269-280
16. Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, Dunning BE, Deacon CF, Holst JJ, Foley JE 2005 Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 90:4888-4894
17. Deacon CF, Wamberg S, Bie P, Hughes TE, Holst JJ 2002 Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. J Endocrinol 172:355-362
18. Hansotia T, Baggio LL, Delmeire D, Hinke SA, Yamada Y, Tsukiyama K, Seino Y, Holst JJ, Schuit F, Drucker DJ 2004 Double incretin receptor knock-out (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes 53:1326-1335
19. Gautier JF, Fetita S, Sobngwi E, Salaun-Martin C 2005 Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes Metab 31:233-242
20. Mentlein R 1999 Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides. Regul Pept 85:9-24
21. Zhu L, Tamvakopoulos C, Xie D, Dragovic J, Shen X, Fenyk-Melody JE, Schmidt K, Bagchi A, Griffin PR, Thornberry NA, Sinha RR 2003 The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1-38). J Biol Chem 278:22418-22423
22. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W 1993 Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36:741-744